At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Astaxanthine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and National Institute of Health Stroke Scale Score of Acute Ischemic Stroke Patients: A Randomized Trial
In Brief
A Phase 1 clinical trial evaluating Astaxanthine and Placebo Oral Tablet for Cerebral Stroke and 2 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This is an interventional randomized, controlled trial in analyzing the effects of astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic stroke patients. According to published studies, it was hypothesized that acute ischemic stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and lower NIHSS score compared to the control group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Stroke, Malondialdehyde, Oxidative Stress
CountriesIndonesia
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
Primary CompletionJun 2010
First PostedMay 2019
TodayJul 2026
First PostedMay 10, 2019
Enrollment StartMar 23, 2010
Primary CompletionJun 9, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.1 years ago
Interventions
Astaxanthinedrug
Placebo Oral Tabletdrug